Management of hepatic metastasis from colorectal cancers: an update.
(2008) Journal of Hepato-Biliary-Pancreatic Surgery — Vol. 15, n° 6, p. 570-580 (2008)
Files
Sharma-2008-Managementofhepaticmetastasis.pdf
Restricted Access - Adobe PDF
- 171.42 KB
Details
- Authors
- Abstract
- Approximately 50%-60% of patients with colorectal cancers will develop liver lesions in their life span. Despite the potential of surgical resection to provide long-term survival in this subset of patients, only 15%-20% are found to be resectable. The introduction of new neoadjuvant chemotherapeutic agents and the expanding criteria of resection have enhanced the overall 5-year survival from 30% to 60% in the past decade. The use of technical innovations such as staged resection; portal vein embolization, and repeat resection have allowed higher resection rates in patients with bilobar disease. Extrahepatic primary and liver-exclusive recurrent disease no longer represent an absolute contraindication to resection. The role of regional therapy using hepatic arterial infusion is being redefined for liver-exclusive unresectable disease. Adjuvant chemotherapy in combination with regional therapies is being looked at from fresh perspectives. Ablative approaches have gained a firm role both as an adjunct to surgical resection and in the management of patients who are not surgical candidates. Overall, the management of hepatic metastasis from colorectal cancers requires a multimodal approach.
- Affiliations
INTEGRIS Baptist Medical Center, Oklahoma City, USA Nazih Zudhi Transplant Institute
Citations
Sharma, S., Camci, C., & Jabbour, N. (2008). Management of hepatic metastasis from colorectal cancers: an update. Journal of Hepato-Biliary-Pancreatic Surgery, 15(6), 570-580. https://doi.org/10.1007/s00534-008-1350-x (Original work published 2008)